Skip to main content

Table 2 Successful use of letrozole in the treatment of endometriosis associated symptoms

From: The emerging use of aromatase inhibitors for endometriosis treatment

Patient group Summary of Results Reference
Pre-menopausal women (N = 1)
(endometriosis resistant to conventional therapy)
Decreased pelvic pain, affect on implant mass not determined [23] Verme & Konje
Pre-menopausal women (N = 10)
(endometriosis resistant to conventional therapy)
Decrease in pelvic pain
Decrease in implant mass
[24] Ailawadi et al.
Pre-menopausal women (N = 82)
(intolerant/failed previous treatment, severe pain symptoms, N = 37 Letrozole + norethisterone acetate vs. N = 38 Norethisterone acetate alone)
Decrease in pelvic pain and deep dyspareunia, affect on implant mass unknown [25] Ferrero et al.
Pre-menopausal women (N = 2)
(bladder endometriosis, non-responsive to conventional therapy, pelvic pain and urinary symptoms)
Decreased pelvic pain and urinary symptoms, affect on implant mass not determined [26] Ferrero et al.
Women with colorectal endometriosis
(N = 6; pain and intestinal symptoms)
Decreased pain and intestinal symptoms, affect on implant mass unknown [27] Ferrero et al.
Pre-menopausal women (N = 5)
(recurrent ovarian endometriosis, chronic pelvic pain)
Decreased pelvic pain, decreased implant mass [28] Lall et al.
Pre-menopausal women (N = 1)
(recurrent endometriosis resistant to conventional therapy, pelvic pain dyspareunia)
Decreased pelvic pain and dyspareunia, affect on implant mass not determined [29] Razzi et al.
Post-menopausal woman (N = 1)
(recurrent endometrioma, pain)
Decreased pain, decrease in implant mass [30] Fatemi et al.
Post-menopausal woman (N = 1)
(severe pelvic pain)
Decreased pelvic pain, affect on implant mass unknown [31] Mousa et al.
Post-menopausal woman (N = 1)
(recurrent abdominal wall endometriosis)
Decreased implant mass [32] Sasson & Taylor